LEXARIA BIOSCIENCE CORP (LEXX) Stock Overview
USA - NASDAQ:LEXX - US52886N4060 - Common Stock
LEXX Key Statistics, Chart & Performance
The current stock price of LEXX is 1.05 USD. In the past month the price increased by 17.98%. In the past year, price decreased by -65.23%.
LEXX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.86 | 685.75B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 432.80B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.15 | 247.10B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.97 | 239.37B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.61 | 228.69B | ||
| MRK | MERCK & CO. INC. | 10.2 | 196.23B | ||
| PFE | PFIZER INC | 7.01 | 135.09B | ||
| SNY | SANOFI-ADR | 10.21 | 111.07B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.56 | 89.80B | ||
| GSK | GSK PLC-SPON ADR | 8.86 | 80.28B | ||
| ZTS | ZOETIS INC | 23.07 | 63.60B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.83 | 46.55B |
Related stock screener links
About LEXX
Company Profile
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The firm operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Company Info
LEXARIA BIOSCIENCE CORP
100 - 740 Mccurdy Road
Kelowna BRITISH COLUMBIA V1X 2P7 CA
CEO: Christopher Bunka
Employees: 7
Phone: 12507656424
LEXARIA BIOSCIENCE CORP / LEXX FAQ
What is the stock price of LEXARIA BIOSCIENCE CORP today?
The current stock price of LEXX is 1.05 USD. The price decreased by -31.37% in the last trading session.
What is the ticker symbol for LEXARIA BIOSCIENCE CORP stock?
The exchange symbol of LEXARIA BIOSCIENCE CORP is LEXX and it is listed on the Nasdaq exchange.
On which exchange is LEXX stock listed?
LEXX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LEXARIA BIOSCIENCE CORP stock?
8 analysts have analysed LEXX and the average price target is 6.12 USD. This implies a price increase of 482.86% is expected in the next year compared to the current price of 1.05. Check the LEXARIA BIOSCIENCE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LEXARIA BIOSCIENCE CORP worth?
LEXARIA BIOSCIENCE CORP (LEXX) has a market capitalization of 20.54M USD. This makes LEXX a Nano Cap stock.
How many employees does LEXARIA BIOSCIENCE CORP have?
LEXARIA BIOSCIENCE CORP (LEXX) currently has 7 employees.
Is LEXARIA BIOSCIENCE CORP (LEXX) expected to grow?
The Revenue of LEXARIA BIOSCIENCE CORP (LEXX) is expected to grow by 69.94% in the next year. Check the estimates tab for more information on the LEXX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LEXARIA BIOSCIENCE CORP (LEXX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LEXX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LEXX, evaluating the profitability, health, valuation and growth aspects
- LEXARIA BIOSCIENCE CORP (LEXX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LEXARIA BIOSCIENCE CORP (LEXX) Sales and EPS estimates to see what analysts future expectations are.
- LEXARIA BIOSCIENCE CORP (LEXX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LEXARIA BIOSCIENCE CORP (LEXX) Insider and Institutional Ownership to learn about the owners and their transactions.
- LEXARIA BIOSCIENCE CORP (LEXX) Stock Chart to make your own analysis
- LEXARIA BIOSCIENCE CORP (LEXX) Latest news and press-releases to stay up to date.
Does LEXARIA BIOSCIENCE CORP (LEXX) stock pay dividends?
LEXX does not pay a dividend.
When does LEXARIA BIOSCIENCE CORP (LEXX) report earnings?
LEXARIA BIOSCIENCE CORP (LEXX) will report earnings on 2025-11-24, after the market close.
What is the Price/Earnings (PE) ratio of LEXARIA BIOSCIENCE CORP (LEXX)?
LEXARIA BIOSCIENCE CORP (LEXX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.66).
What is the Short Interest ratio of LEXARIA BIOSCIENCE CORP (LEXX) stock?
The outstanding short interest for LEXARIA BIOSCIENCE CORP (LEXX) is 2.27% of its float. Check the ownership tab for more information on the LEXX short interest.
LEXX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LEXX. When comparing the yearly performance of all stocks, LEXX is a bad performer in the overall market: 89.77% of all stocks are doing better.
LEXX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LEXX. LEXX has a great financial health rating, but its profitability evaluates not so good.
LEXX Financial Highlights
Over the last trailing twelve months LEXX reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS decreased by -50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168.97% | ||
| ROE | -205.16% | ||
| Debt/Equity | 0 |
LEXX Forecast & Estimates
8 analysts have analysed LEXX and the average price target is 6.12 USD. This implies a price increase of 482.86% is expected in the next year compared to the current price of 1.05.
For the next year, analysts expect an EPS growth of -52.26% and a revenue growth 69.94% for LEXX